InMed Pharmaceuticals Inc (INM) 1.75 USD (-0.04%) | Healthcare & Biotech NASDAQ

InMed Pharmaceuticals is a biopharmaceutical company focused on developing cannabinoid-based medicines for various chronic diseases.

Price history of InMed Pharmaceuticals Inc

Performance & Momentum

6 Months 53.38 %

1 Year 75.34 %

3 Years 97.55 %

5 Years 99.95 %

Momentum

Unlock this indicator

Law Firm Investigates InMed Board

Published on May 19, 2026, this notice from Brodsky & Smith says it has opened an investigation into alleged violations by the board of directors of InMed Pharmaceuticals. Such proceedings typically weigh on the stock, as they add uncertainty around governance and potential shareholder claims.

globenewswire.com • governance, shareholder litigation

Strategic Analysis

InMed Pharmaceuticals Inc • 2026

InMed Pharmaceuticals positions itself as a biopharmaceutical company specializing in the development of innovative cannabinoid treatments for chronic conditions, addressing an emerging medical niche. Its model is based on the search for differentiated therapeutic formulations, aiming to harness the medical potential of cannabis in segments where needs remain unmet.

Strengths

Targeted expertise in cannabinoids, an innovative field with growing therapeutic potential
Focus on chronic diseases with high unmet medical demand
Canadian company benefiting from a progressive regulatory framework for cannabis-based products

Weaknesses

Structurally degraded stock performance over the long term, indicating operational or clinical challenges
Lack of recent catalysts or favorable news, limiting short-term visibility

Momentum

The momentum is currently very weak, reflecting a phase of investor disengagement and limited confidence in immediate prospects. This situation requires heightened vigilance from investors, who will need to wait for clear signs of recovery or clinical validation before considering a more assertive position.

Analysis performed 2 months ago